Examining Genetic Factors That Affect the Severity of 22q11.2 Deletion Syndrome

计划入组 1,000 人 · 首次发布于 2007 年 11 月 12 日

Resolution of Primary Immune Defect in 22q11.2 Deletion Syndrome

计划入组 43 人 · 首次发布于 2015 年 6 月 2 日

Social Cognition Training and Cognitive Remediation

计划入组 3 人 · 首次发布于 2017 年 9 月 15 日

drug candidate (22q11.2 Deletion Syndrome)

Drug Candidate for 22q11.2 Deletion Syndrome (Herophilus)

22q11 Deletion Syndrome(Aelis Farma)

ALPORT SYNDROME FOUNDATION

United States

International Rett Syndrome Foundation

United States

RETT SYNDROME RESEARCH TRUST

United States

Nobias Therapeutics' NB-001 Shows Promise for 22q11.2 Deletion Syndrome

Antioxidant Therapy Bypasses Genetic Defect in 22q11.2 Deletion Syndrome via Alternative Gene Networks

Synaptiq Therapeutics Launches with Acquisition of SYN-001, a Phase II-Ready Small Molecule for 22q11.2 Deletion Syndrome